Cardiol Therapeutics (TSE:CRDL) Shares Down 13.9% – What’s Next?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price traded down 13.9% during trading on Monday . The company traded as low as C$1.24 and last traded at C$1.30. 516,265 shares were traded during trading, an increase of 374% from the average session volume of 108,850 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Trading Down 14.6%

The company has a market cap of C$129.00 million, a P/E ratio of -3.15 and a beta of 1.31. The firm’s 50 day moving average is C$1.50 and its two-hundred day moving average is C$1.65. The company has a quick ratio of 6.84, a current ratio of 2.49 and a debt-to-equity ratio of 1.59.

Cardiol Therapeutics (TSE:CRDL) last announced its earnings results on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. As a group, equities research analysts anticipate that Cardiol Therapeutics Inc. will post -0.49 EPS for the current year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.